莎普爱思(603168.SH)：获得硫酸特布他林雾化吸入用溶液《药品注册证书》

Core Viewpoint - The company Shapuaisi (603168.SH) has received a drug registration certificate from the National Medical Products Administration for its nebulized solution of Terbutaline Sulfate, which is intended to alleviate bronchial asthma, chronic bronchitis, emphysema, and other pulmonary diseases associated with bronchospasm [1] Company Summary - Shapuaisi has been granted a drug registration certificate (Certificate No. 2025S02611) for its nebulized solution of Terbutaline Sulfate [1] - The approved product is designed to provide relief for patients suffering from bronchial asthma, chronic bronchitis, emphysema, and other related pulmonary conditions [1]